Product nameHuman KIF1B peptide
See all KIF1B proteins and peptides
Purity70 - 90% by HPLC.
Our Abpromise guarantee covers the use of ab74827 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
- If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
- Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
- Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
- Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Information available upon request.
- Charcot Marie Tooth neuropathy 2A
- CMT 2
- CMT 2A
RelevanceKIF1B, or kinesin-like protein (Klp) functions as a motor for mitochondrial transport, and has a microtubule plus end-directed motility. The KIF1B beta isoform is abundant in brain, while the alpha isoform is abundant in skeletal muscle. Mutations in the KIF1B gene are the cause of Charcot-Marie-Tooth disease type 2A1, which is a primary peripheral axon neuropathy. The KIF1B beta isoform is down-regulated in sporadic amyotrophic lateral sclerosis (ALS).
Cellular localizationCytoplasmic and Mitochondrial
ab74827 has not yet been referenced specifically in any publications.